Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

<
<<
Previous
Page 1 of 18
Next
>>
>
1 to 25 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC1806	Sirolimus	3	72	sigmoid	sigmoid	HCC1806 rapamycin 0 3 72	8	3.249	0.223	0.805	0.162	0.000183	0.746	0.1	0.663	0.0382	NA	1.05	0.717	0.76	1e-05	0.657	0.1	0.68	0.0328	NA
HCC1806	WYE-125132	3	72	sigmoid	sigmoid	HCC1806 WYE-132 0 3 72	8	3.242	Inf	0.531	0.255	0.0458	0.517	0.885	0.997	3.48e-08	NA	0.226	0.42	0.663	0.0335	0.402	0.855	0.996	8.79e-08	NA
HCC1806	Everolimus	3	72	sigmoid	sigmoid	HCC1806 everolimus 0 3 72	8	3.239	Inf	0.813	0.159	0.000271	0.812	0.356	0.879	0.00175	NA	Inf	0.727	0.765	0.00022	0.729	0.377	0.879	0.00177	NA
HCC1806	Pictilisib	3	72	sigmoid	sigmoid	HCC1806 pictilisib 0 3 72	8	3.234	14.1	0.818	0.0423	52.2	-0.98	0.831	0.814	0.00649	NA	11.3	0.734	0.935	11.3	0.0	0.849	0.773	0.0116	NA
HCC1806	Alpelisib	3	72	flat	flat	HCC1806 alpelisib 0 3 72	8	3.224	Inf	0.93	0.0502	0.0	0.93	0.01	-0.335	1.0	0.948	Inf	0.891	0.921	0.0	0.891	0.01	-0.351	1.0	0.919
HCC1806	Omipalisib	3	72	sigmoid	sigmoid	HCC1806 omipalisib 0 3 72	8	3.217	0.147	-0.221	0.437	0.71	-0.707	0.559	0.981	7.41e-06	NA	0.0642	0.0481	0.54	0.0538	0.0749	0.919	0.979	9.93e-06	NA
HCC1806	Torin2	3	72	sigmoid	sigmoid	HCC1806 Torin2 0 3 72	8	3.212	0.0678	-0.0927	0.522	0.0798	-0.12	1.32	0.996	6.56e-08	NA	0.0486	0.079	0.492	0.0442	0.0528	1.17	0.995	1.09e-07	NA
HCC1806	Torin1	3	72	sigmoid	sigmoid	HCC1806 Torin1 0 3 72	8	3.208	0.537	0.332	0.278	0.165	0.271	0.662	0.988	1.91e-06	NA	0.186	0.272	0.651	0.0697	0.26	0.75	0.992	4.55e-07	NA
HCC1806	PIK-93	3	72	sigmoid	sigmoid	HCC1806 PIK-93 0 3 72	8	3.206	56.0	0.873	0.0337	320.0	-0.872	0.579	0.859	0.00279	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
HCC1806	Trametinib	3	72	sigmoid	sigmoid	HCC1806 trametinib 0 3 72	8	3.204	Inf	0.822	0.12	0.00981	0.829	0.872	0.97	2.67e-05	NA	Inf	0.742	0.822	0.00864	0.752	0.892	0.97	2.67e-05	NA
HCC1806	AZD-6482	3	72	flat	flat	HCC1806 AZD6482 0 3 72	8	3.201	Inf	1.0	0.00122	0.0	1.0	0.01	-0.0063	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00515	1.0	0.998
HCC1806	MK2206	3	72	sigmoid	sigmoid	HCC1806 MK-2206 0 3 72	8	3.199	74.1	0.843	0.0434	320.0	-0.491	0.468	0.981	6.96e-06	NA	Inf	0.769	0.934	4.46	0.507	0.566	0.976	1.46e-05	NA
HCC1806	Dactolisib	3	72	sigmoid	sigmoid	HCC1806 dactolisib 0 3 72	8	3.196	0.193	0.0324	0.393	0.437	-0.302	0.579	0.986	2.91e-06	NA	0.0977	0.121	0.559	0.093	0.0151	0.619	0.986	2.47e-06	NA
HCC1806	Buparlisib	3	72	sigmoid	sigmoid	HCC1806 buparlisib 0 3 72	8	3.195	0.808	-0.257	0.203	0.96	-0.303	2.74	1.0	2.03e-11	NA	0.69	0.0423	0.803	0.674	0.033	2.99	0.999	1.17e-09	NA
HCC1806	KIN001-244	3	72	flat	flat	HCC1806 KIN001-244 0 3 72	8	3.195	Inf	0.988	0.0203	0.0	0.988	0.01	-0.0575	1.0	0.982	Inf	0.981	0.968	0.0	0.981	0.01	-0.0553	1.0	0.972
HCC1806	BX-912	3	72	sigmoid	sigmoid	HCC1806 BX-912 0 3 72	8	3.193	1.09	0.234	0.126	0.897	0.217	2.99	0.999	2.85e-09	NA	0.894	0.214	0.853	0.753	0.205	3.07	0.997	2.86e-08	NA
HCC1806	XL147	3	72	flat	flat	HCC1806 pilaralisib 0 3 72	8	3.185	Inf	1.02	0.000871	0.0	1.02	0.01	-2.12e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000107	1.0	1.0
HCC1806	AZD8055	3	72	sigmoid	sigmoid	HCC1806 AZD8055 0 3 72	8	3.185	Inf	0.593	0.215	0.0523	0.583	1.19	0.995	1.36e-07	NA	0.521	0.484	0.716	0.0427	0.471	1.15	0.996	7.15e-08	NA
HCC1806	AS605240	3	72	sigmoid	sigmoid	HCC1806 AS-605240 0 3 72	8	3.181	Inf	0.923	0.011	0.57	0.923	2.81	0.936	0.000257	NA	Inf	0.883	0.983	0.559	0.882	2.81	0.931	0.000333	NA
HCC1806	ZSTK474	3	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 3 72	8	3.162	Inf	0.654	0.0322	1.18	0.65	4.68	0.99	1.03e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
HCC1806	GDC-0980	3	72	sigmoid	sigmoid	HCC1806 apitolisib 0 3 72	8	3.149	1.8	0.418	0.132	0.77	0.31	1.14	0.995	1.41e-07	NA	0.947	0.339	0.832	0.475	0.292	1.27	0.993	2.95e-07	NA
HCC1806	CAL-101	3	72	flat	flat	HCC1806 idelalisib 0 3 72	8	3.147	Inf	1.02	-0.00869	0.0	1.02	0.01	-0.594	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.587	1.0	1.02
HCC1806	TGX221	3	72	flat	flat	HCC1806 TGX-221 0 3 72	8	3.132	Inf	1.0	-0.0101	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	PI103	3	72	sigmoid	sigmoid	HCC1806 PI-103 0 3 72	8	3.126	Inf	0.91	0.00588	1.72	0.873	1.43	0.782	0.0103	NA	Inf	0.866	0.992	1.61	0.817	1.44	0.762	0.0134	NA
Hs 578T	Pictilisib	3		sigmoid	sigmoid	Hs578T pictilisib 3	8	2.911	2.33	0.471	0.168	0.364	0.403	0.883	0.996	5.24e-08	NA	0.97	0.409	0.794	0.228	0.374	0.952	0.996	5.98e-08	NA

<
<<
Previous
Page 1 of 18
Next
>>
>
1 to 25 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)